| Fiscal period | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Period End Date | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 |
|---|
| Revenues : Product sales | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Contract revenue | 27.48 | 19.03 | 19.22 | 63.96 | 42.66 | -- | -- | -- | -- | -- |
| Revenues : Royalties | 108.77 | 83.91 | 72.53 | 48.93 | 33.80 | 46.98 | 128.56 | 88.69 | 59.42 | 38.19 |
| Revenues : Sale of royalty rights, net | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenues:Material sales | -- | -- | -- | -- | -- | 31.49 | 29.12 | 22.07 | 22.50 | 27.66 |
| Captisol | 30.88 | 28.37 | 104.50 | 164.25 | 109.96 | -- | -- | -- | -- | -- |
| Revenues : Collaborative research and development and other revenues | -- | -- | -- | -- | -- | 41.82 | 93.77 | 30.35 | 27.05 | 6.06 |
| Total Revenues | 167.13 | 131.31 | 196.25 | 277.13 | 186.42 | 120.28 | 251.45 | 141.10 | 108.97 | 71.91 |
| Cost of Products Sold | -- | -- | -- | -- | -- | 11.35 | 6.34 | 5.37 | 5.57 | 5.81 |
| Cost of Captisol | 11.07 | 10.51 | 52.83 | 62.18 | 30.42 | -- | -- | -- | -- | -- |
| Amortization of intangibles | 32.96 | 33.65 | 34.24 | 47.17 | 23.44 | 16.86 | 15.79 | 12.12 | 10.64 | -- |
| Research and development | 21.43 | 24.54 | 36.08 | 69.01 | 59.39 | 55.91 | 27.86 | 26.89 | 21.22 | 13.38 |
| Write-off of acquired in-process research and development | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 |
| General and Administrative | 78.65 | 52.79 | 70.06 | 57.48 | 64.44 | 41.88 | 37.73 | 28.65 | 26.62 | 24.38 |
| Other operating income | -- | -- | -- | 37.60 | -- | -- | -- | -- | -- | -- |
| Lease termination costs | -- | -- | -- | -- | -- | -- | -- | -- | (1.03) | (1.02) |
| Co-promotion | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Co-promote termination charges | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Accretion of deferred gain on sale leaseback | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Gain from sale of Promacta license | -- | -- | -- | -- | -- | 812.80 | -- | -- | -- | -- |
| Gain from sale of Vernalis R&D | -- | -- | -- | -- | 17.11 | -- | -- | -- | -- | -- |
| Gain on sale of Pelican | -- | 2.12 | -- | -- | -- | -- | -- | -- | -- | -- |
| Financial royalty assets impairment | (30.57) | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Fair value adjustments to partner program derivatives | (15.06) | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Total Operating Expenses | 189.74 | 121.49 | 193.21 | 198.24 | 177.69 | 126.00 | 87.73 | 73.03 | 65.09 | 44.59 |
| Operating income | (22.61) | 11.94 | -- | 78.90 | 25.85 | 807.08 | 163.73 | 68.08 | 43.89 | 27.33 |
| Interest expense | 3.04 | 0.66 | 1.80 | 19.63 | 27.42 | 35.75 | 48.28 | 11.40 | 12.18 | 11.80 |
| Gain on deconsolidation of Viking Therapeutics, Inc | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | 28.19 |
| Gain on sale leaseback | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Gain (loss) from short-term investments | 75.02 | 46.37 | 28.54 | (4.00) | (16.93) | -- | -- | -- | -- | -- |
| Equity in net losses from Viking Therapeutics | -- | -- | -- | -- | -- | 2.89 | 50.19 | (2.05) | (23.13) | -- |
| Interest income | 8.06 | 7.71 | 2.05 | 0.89 | 8.08 | 28.43 | 14.00 | -- | -- | -- |
| Other, net | (54.92) | (1.95) | 4.19 | (8.86) | (0.11) | (6.01) | (6.31) | 5.18 | 2.72 | 1.77 |
| Debt conversion expense | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Gain on derivative instruments | -- | 0.25 | -- | -- | -- | -- | -- | -- | -- | -- |
| Decrease in liability for contingent value rights | -- | -- | -- | -- | -- | -- | -- | (2.58) | (3.33) | (5.01) |
| Pro-rata non-cash net losses of Viking Therapeutics, Inc | -- | -- | -- | -- | -- | -- | -- | -- | -- | (5.14) |
| Total other (expense) income, net | 25.12 | 51.72 | 32.97 | (31.60) | (36.38) | (10.44) | 9.60 | (10.85) | (35.93) | -- |
| Income (loss) from continuing operations before income taxes | 2.52 | 63.66 | 36.01 | 47.30 | (10.54) | 796.64 | 173.33 | 57.23 | 7.96 | 35.33 |
| Deferred benefit: Federal | (17.77) | 9.37 | -- | (7.36) | (15.67) | 74.63 | 29.93 | 44.08 | 10.53 | (193.40) |
| Deferred benefit : State | 0.08 | 0.66 | -- | (1.26) | (3.38) | 0.20 | (0.19) | 0.23 | (0.24) | (26.22) |
| Income tax benefit from continuing operations | 6.55 | 9.84 | 41.23 | (9.84) | (7.55) | 167.34 | 30.01 | 44.68 | 10.33 | (219.60) |
| Current Benefit : Federal | 18.28 | (1.19) | -- | (1.19) | 10.89 | 89.47 | 0.00 | 0.00 | 0.02 | 0.01 |
| Current Benefit : State | 0.72 | 0.22 | -- | (0.03) | 0.59 | 3.10 | 0.42 | 0.11 | 0.01 | 0.01 |
| Current Benefit : Foreign | 3.36 | 0.78 | -- | -- | 0.02 | (0.07) | -- | -- | -- | -- |
| Income from continuing operations including noncontrolling interests | -- | -- | -- | -- | -- | -- | -- | -- | -- | 254.93 |
| Less: Net loss attributable to noncontrolling interests | -- | -- | -- | -- | -- | -- | -- | -- | -- | (2.38) |
| Loss from continuing operations | (4.03) | 53.82 | (5.22) | -- | -- | -- | 143.32 | 12.56 | (2.37) | 257.31 |
| Income from Discontinued Operations | -- | (1.67) | (28.14) | -- | -- | -- | 0.00 | 0.00 | 0.73 | 0.00 |
| Discontinued operations : Income (loss) from discontinued operations before income taxes | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Discontinued operations : Gain on sale of AVINZA Product Line before income taxes | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Discontinued operations : Gain (loss) on sale of Oncology Product Line before income taxes | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | 1.14 | -- |
| Discontinued operations : Income tax benefit (expense) on discontinued operations | -- | -- | -- | -- | -- | -- | -- | -- | (0.41) | -- |
| Loss before cumulative effect of a change in accounting principle | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cumulative effect of changing method of accounting for variable interest entity | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net income | (4.03) | 52.15 | (33.36) | 57.14 | (2.99) | 629.30 | -- | -- | (1.64) | -- |
| Net loss attributable to noncontrolling interests | -- | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- |
| Net Income (loss) Available to Common Shareholders | (4.03) | 52.15 | (33.36) | 57.14 | (2.99) | 629.30 | 143.32 | 12.56 | (1.64) | 257.31 |
| EPS (Basic) : Loss from continuing operations | (0.22) | 3.11 | (0.31) | -- | -- | -- | 6.77 | 0.60 | (0.11) | 13.00 |
| EPS (Basic) : Income (loss) from discontinued operations | -- | (0.10) | (1.67) | -- | -- | -- | -- | -- | 0.04 | 0.00 |
| EPS (Basic) : Cumulative effect of changing method of accounting for variable interest entity | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Earnings Per Share (Basic) | (0.22) | 3.02 | (1.98) | 3.44 | (0.18) | 33.13 | 6.77 | 0.60 | (0.08) | 13.00 |
| EPS (Diluted) : Loss from continuing operations | (0.22) | 3.03 | (0.31) | -- | -- | -- | 5.96 | 0.53 | (0.11) | 12.12 |
| EPS (Diluted) : Income (loss) from discontinued operations | -- | (0.09) | (1.67) | -- | -- | -- | -- | -- | 0.04 | 0.00 |
| EPS (Diluted) : Cumulative effect of changing method of accounting for variable interest entity | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Earnings Per Share (Diluted) | (0.22) | 2.94 | (1.98) | 3.31 | (0.18) | 31.85 | 5.96 | 0.53 | (0.08) | 12.12 |
| Weighted Average Shares Outstanding (Basic) | 18.29 | 17.30 | 16.87 | 16.63 | 16.19 | 19.00 | 21.16 | 21.03 | 20.83 | 19.79 |
| Weighted Average Shares Outstanding (Diluted) | 18.29 | 17.76 | 16.87 | 17.25 | 16.19 | 19.76 | 24.07 | 23.48 | 20.83 | 21.23 |